NEWARK, Calif., April 24, 2015 (GLOBE NEWSWIRE) — StemCells, Inc. (Nasdaq:STEM) today announced the pricing of an underwritten public offering of common stock and warrants with a public offering price of $0.70 for a fixed combination of one share of common stock and a warrant to purchase three-quarters of a share of common stock. The warrants have an exercise price of $0.85 per share, are exercisable immediately, and will expire five years from the date of issuance. The Company expects to receive gross proceeds of approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Company has also granted the underwriters a 30 day option to purchase up to an additional 5,357,250 shares of common stock and/or warrants to purchase up to an additional 4,017,938 shares of common stock to cover over-allotments, if any.
The offering is expected to close on or about April 29, 2015, subject to customary closing conditions.
Maxim Group LLC is acting as sole book-running manager and Chardan Capital Markets is acting as co-manager for the offering.